Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Cancer Immunotherapy

Posts tagged ‘IMpassion130’

Not in Madrid – Saturday was an incredibly busy day at ESMO20 with live oral presentations on multiple channels and the first of the Presidential Sessions.

TDF London 2014A conference can be like watching the Tour de France (TdF) which ends this weekend. If you’re standing on the route, you wait a long time for it to come along and then the peloton passes by in a flash. We experienced this in London back in 2014, where there was only a brief moment of time to capture the memory.

Like the TdF, cancer drug development is a team sport that takes place in a dynamic, competitive environment with moments of individual brilliance.

Yesterday at the ESMO20 virtual congress we listened to presentations, discussions, Q&A, interacted with experts, and put together two separate highlights posts, which captures the day so that BSB readers will not have to worry the Congress will pass them by.

When we were all going to live meetings, we anecdotally heard many people in Pharmaland used our conference coverage for writing their trip reports or getting a sense of the nuances around key trials, especially if they were in company meetings most of the time!

If you’re looking to get a picture of what was at ESMO20 then then do consider purchasing access. We put up a paywall seven years ago in September 2013 as a novel way to fund independent science journalism. Thanks to everyone who has been part of a journey that continues on.

In part 1 of our coverage of Saturday at ESMO20, we review and discuss some of the new developments in the breast cancer niche (catch up with part 2 covering key topics in lung, renal and urothelial cancers)…

To learn more from our oncology analysis and get a heads up on insights and commentary pertaining to ESMO 2020, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

One of the emerging challenges of the IMpassion130 trial of the combination of nab-paclitaxel and atezolizumab versus nab-paclitaxel alone in triple negative breast cancer (TNBC) is that pathologists can’t reliably read PD-L1 on immune cells.

Georgia State Capitol in Atlanta

This issue came up in an insightful talk by David Rimm MD PhD (@RimmPathology), Professor, Departments of Pathology and Medicine (Oncology) at Yale in an education session at this year’s AACR annual meeting in Atlanta where he spoke about, “Predicting immunotherapy response with protein-based tools: PD-L1 and beyond.”

BSB readers will recall Dr Rimm was a hard hitting discussant of the CheckMate–227 trial data for the combination of nivolumab and ipilimumab in first-line non-small cell lung cancer (NSCLC) at AACR18. He correctly predicted that tumor mutational burden (TMB) as a biomarker would predict PFS but not overall survival, based on an analysis of their cohort at Yale. He turned out to be right!

The implication of this was that BMS subsequently withdrew their EU/US regulatory filings for CM227 in 1L NSCLC when the hazard ratios (HR) for high and low TMB turned out to be identical.

If you missed it, do listen to the episode 22 of the Novel Targets Podcast we produced from AACR18 (Link), where we took a closer look at TMB as a biomarker, and the phase 3 lung cancer clinical data presented at the meeting.

Will we see challenges emerge with the Ventana SP142 assay?  What about the implications for Merck’s KEYNOTE-355 trial in TNBC?

In this BSB post, we discuss these issues and explore many of the nuances that readers should be aware of in TNBC.

In addition to Dr Rimm’s candid and hard hitting interview, we also invited Professor Sherene Loi (@LoiSher) to review Dr Rimm’s commentary and offer a clinical perspective on the points he raised.

She’s a consultant medical oncologist at the Peter MacCullum Centre in Australia, where she holds the National Breast Cancer Foundation of Australia Endowed Chair and is head of the Translational Breast Cancer Genomics and Therapeutic Laboratory.

Professor Loi is also one of the authors of the paper published in The New England Journal of Medicine that reported the results of the IMPassion130 trial.

If you’d like to read Dr Rimm’s candid interview and Professor Loi’s clinical perspective, become a subscriber to BSB and support independent science journalism. As of today, 75% of our subscribers are repeat buyers – do consider joining them!

In the second part of the interview with Dr Rimm (to be published separately), we’ll hear about some of the new data his lab presented at AACR19 and where he sees the future for TMB and other immune biomarkers.

To learn more and get a heads up on our latest oncology coverage, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Free Email Updates
Subscribe to new post alerts, offers, and additional content!
We respect your privacy and do not sell emails. Unsubscribe at any time.
error: Content is protected !!